Inqovi (decitabine and cedazuridine) — United Healthcare
Myelodysplastic syndrome (MDS) including previously treated and untreated, de novo and secondary MDS with French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML])
Initial criteria
- Diagnosis of myelodysplastic syndrome [e.g., previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia (CMML))]
- AND Patient is intermediate-1, intermediate-2, or high-risk per the International Prognostic Scoring System (IPSS)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Inqovi therapy
Approval duration
12 months